<DOC>
	<DOCNO>NCT00548769</DOCNO>
	<brief_summary>Sufficient subject confirm diagnosis MS ( EDSS score 6.5 ) , recruit ensure 30 subject ( approx . equal number gender ) complete study . Subjects undergo screen visit , four study day , separate washout period least 7 day , different firategrast batch drug substance administer , follow-up visit .</brief_summary>
	<brief_title>Firategrast ( SB683699 ) Surface Area Study Multiple Sclerosis Patients</brief_title>
	<detailed_description>An open-label , randomise , four period crossover study investigate relative pharmacokinetic profile tablet three batch firategrast different surface area two different tablet formulation contain batch firategrast , give single 900mg dos male female subject diagnosis Multiple Sclerosis</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Male female subject age 1865 year inclusive diagnosis MS EDSS 06.5 inclusive Screening visit QTc &lt; 450msec A female subject eligible enter study nonchildbearing potential , childbearing potential , negative urine pregnancy test Screening , agree consistent correct use adequate contraception Provide sign date write informed consent prior study participation The subject able understand comply protocol requirement , instruction protocolstated restriction A negative urine drug abuse test . No evidence pulmonary tuberculosis verify negative chest Xray within past 6 month Subjects receive corticosteroid within 4 week Screening treatment MS . If nonsystemic steroid use chronic inflammatory condition , subject may include discretion investigator discussion GSK medical monitor . Use βinterferon product , glatiramer acetate azathioprine within 3 month Screening , use Mitoxantrone within 12 month Screening . Subjects receive therapy affect immune system ( IVIg , cyclophosphamide , plasmapheresis , immunosuppressive immunomodulatory treatment ) past may include case case basis discussion GSK medical monitor . None treatment allow study Previous exposure alemtuzumab , natalizumab bone marrow transplantation whole body irradiation . Subjects cardiac pacemaker type metal implant contraindication MRI ( include know allergy gadolinium ) . Use 4aminopyridine , rosiglitazone , pioglitazone compound metabolise primarily cytochrome P450 2C8 prohibit Screening throughout study Subjects clinically significant renal laboratory value : subject calculate creatinine clearance &lt; 60ml/min Subjects local urinalysis finding outside range define protocol screening period . Presence clinically significant hepatic laboratory value CD4 count &lt; 500 cells/µl , CD4 : CD8 &lt; 1.0 , idiopathic CD4/CD8 lymphopenia secondary lymphopenia Screening . JCV DNA detect plasma buffy coat use PCR Any finding MRI brain MS , except benign finding require evaluation treatment impact patient 's neurological health Current history cancer , exclude localize nonmelanoma skin cancer . Uncontrolled active bacterial , viral , fungal infection . Any previous serious infection discuss GSK medical monitor ( e.g . opportunistic atypical infection ) . History tuberculosis positive chest Xray TB Known congenital acquire immunodeficiency . Any abnormality 12lead ECG Screening clinically significant opinion investigator . Subjects positive hepatitis B , hepatitis C HIV test Screening . Women lactate , pregnant ( positive pregnancy test Screening ) , plan become pregnant course study . Recent history suspicion current drug abuse ( include analgesic abuse ) alcohol abuse within last 6 month prior Screening . Use investigational drug condition MS within 30 day 5 halflives ( whichever longer ) precede Screening . Prior use investigational drug MS discuss GSK medical monitor . Any concurrent illness , disability clinically significant abnormality ( include laboratory test ) may affect interpretation clinical efficacy safety data prevent subject safely complete assessment require protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SB-683699 ,</keyword>
	<keyword>firategrast ,</keyword>
	<keyword>PK ,</keyword>
	<keyword>surface area ,</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>